Ⓐ
PeptiBrief
Evidence Library
randomized_double_blind_pilot_trial · 2012

Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy: a randomized, double-blind pilot study

Heij L|Niesters M|Swartjes M|Hoitsma E|Drent M|Dunckley T|Hohmann A|Cerami A|Brines M|Dahan A · Molecular Medicine
moderateDOI · 10.2119/molmed.2012.00324PMID · 23168581Verified
View source
Plain-English summary

The peptide was generally tolerated and produced exploratory improvements in neuropathic symptoms.

Population
Adults with sarcoidosis and small-fibre-neuropathy symptoms
Sample size
22
Intervention
Subcutaneous ARA-290 or placebo
Outcomes measured
Neuropathic symptoms|Pain|Safety
Key findings
Supported further clinical investigation.
Limitations
Small pilot trial|Short treatment|Exploratory outcomes|Specialist population
Risk of bias
Moderate-to-high risk because of sample size and exploratory design.
Citation
Heij L|Niesters M|Swartjes M|Hoitsma E|Drent M|Dunckley T|Hohmann A|Cerami A|Brines M|Dahan A (2012). Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy: a randomized, double-blind pilot study. Molecular Medicine. https://doi.org/10.2119/molmed.2012.00324
Linked peptides in the PeptiBrief database
ImportantPeptiBrief is an educational information platform. It does not diagnose, prescribe, sell peptides, recommend dosing, encourage self-experimentation or replace qualified medical care. Published scientific evidence is kept separate from community observations and uncertainty.